Allstate Corp Makes New $277,000 Investment in Charles River Laboratories International, Inc. (NYSE:CRL)

Allstate Corp bought a new stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,500 shares of the medical research company’s stock, valued at approximately $277,000.

A number of other institutional investors have also recently made changes to their positions in CRL. Fiduciary Financial Group LLC raised its position in Charles River Laboratories International by 3.9% during the fourth quarter. Fiduciary Financial Group LLC now owns 1,665 shares of the medical research company’s stock valued at $310,000 after purchasing an additional 63 shares during the period. Pinnacle Bancorp Inc. increased its position in shares of Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 65 shares during the last quarter. M&T Bank Corp raised its holdings in Charles River Laboratories International by 3.4% during the 3rd quarter. M&T Bank Corp now owns 2,001 shares of the medical research company’s stock valued at $394,000 after buying an additional 66 shares during the period. Cornerstone Investment Partners LLC lifted its position in Charles River Laboratories International by 3.7% in the fourth quarter. Cornerstone Investment Partners LLC now owns 1,940 shares of the medical research company’s stock worth $358,000 after buying an additional 69 shares during the last quarter. Finally, Metis Global Partners LLC boosted its stake in Charles River Laboratories International by 4.4% during the fourth quarter. Metis Global Partners LLC now owns 1,720 shares of the medical research company’s stock worth $318,000 after buying an additional 72 shares during the period. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Trading Up 2.3 %

NYSE:CRL opened at $149.30 on Thursday. The firm has a 50-day simple moving average of $163.57 and a 200-day simple moving average of $181.69. Charles River Laboratories International, Inc. has a one year low of $142.76 and a one year high of $264.71. The firm has a market cap of $7.63 billion, a P/E ratio of 995.33, a P/E/G ratio of 4.54 and a beta of 1.45. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. During the same quarter in the previous year, the firm posted $2.46 earnings per share. Charles River Laboratories International’s revenue for the quarter was down 1.1% compared to the same quarter last year. Equities analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. UBS Group reissued a “neutral” rating and issued a $185.00 target price (down previously from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. William Blair downgraded shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 22nd. Redburn Atlantic raised Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 target price on the stock in a research note on Monday, March 3rd. The Goldman Sachs Group lowered Charles River Laboratories International from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $190.00 to $170.00 in a research note on Friday, March 21st. Finally, Citigroup upgraded Charles River Laboratories International from a “sell” rating to a “neutral” rating and increased their target price for the stock from $155.00 to $175.00 in a research note on Tuesday, March 4th. One research analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the company’s stock. Based on data from MarketBeat, Charles River Laboratories International currently has a consensus rating of “Hold” and an average target price of $189.77.

Insider Activity at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 4,400 shares of the business’s stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total transaction of $715,000.00. Following the completion of the transaction, the executive vice president now owns 20,013 shares in the company, valued at $3,252,112.50. The trade was a 18.02 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Birgit Girshick bought 1,514 shares of the stock in a transaction on Thursday, February 20th. The stock was purchased at an average price of $164.63 per share, with a total value of $249,249.82. Following the completion of the purchase, the chief operating officer now owns 55,058 shares of the company’s stock, valued at $9,064,198.54. This represents a 2.83 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is owned by corporate insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).